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my, that is, the so-called postpneumonectomy syn-
drome presenting as late pulmonary hypertension or
respiratory failure.
Bronchoplasty was originally designed for patients
with compromised lung function unable to tolerate
pneumonectomy. Since sleeve lobectomy yielded sur-
vival results at least equal to those of pneumonectomy,
as well as better functional results, it became an accept-
ed procedure for patients with lung cancer who have
anatomically suitable tumors, regardless of lung func-
tion.4-7 Functional lung parenchyma can be preserved,
and the reimplanted lobes contribute to postoperative
quality of life. If a second primary lung cancer devel-
ops, subsequent resection may be offered to selected
patients.8,9 Although in most cases sleeve lobectomy
may involve resection of one lobe or of the right middle
and lower lobes, we have tried various complex atypi-
cal resections for patients with noncompromised lung
function and larger centrally located tumors to avoid
pneumonectomy. This study summarizes our experi-
T he risk of perioperative mortality and morbidity isgreater for pneumonectomy than for smaller pul-
monary resections. Some authors have reported that the
30-day operative mortality rate after pneumonectomy is
approximately 6% to 7%.1-3 Moreover, we believe that
pneumonectomy is a disease in itself and should be
avoided at all costs because of the long-term complica-
tions that are sometimes associated with pneumonecto-
my but seldom seen after lobectomy or sleeve lobecto-
Objective: We have tried atypical bronchoplasties in patients with non-
compromised lung function with centrally located cancers to avoid
pneumonectomy. We evaluated the efficacy of extended sleeve lobectomy
in such patients. Methods: Among 157 patients undergoing bronchoplas-
ty for primary non–small cell lung carcinoma, 15 patients underwent
extended sleeve lobectomy. Results: According to the mode of recon-
struction, the 15 patients were classified into 3 groups: (A) anastomosis
between the right main and lower bronchi with resection of the upper
and middle lobes (n = 6), (B) anastomosis between the left main and
basal segmental bronchi with resection of the upper lobe and superior
segment of the lower lobe (n = 4), and (C) anastomosis between the left
main and upper division bronchi with resection of the lingular segment
and lower lobe (n = 5). The tumors were completely resected in all
patients. Pulmonary angioplasty was carried out in 8 patients.
Bronchial reconstruction was successful in all patients. Pulmonary vein
thrombosis resulting from overstretching of the inferior pulmonary vein
occurred in 1 patient of group A and was relieved by completion pneu-
monectomy. There was neither operative mortality nor local recurrence.
Although all patients with stage IIB disease and half of patients with
stage IIIA disease were alive without recurrence (12-106 months), half
of the patients with stage IIIA disease died of distant metastases within
1 year. Conclusions: We suggest that this extended sleeve lobectomy,
which is technically demanding, should be considered in patients with
centrally located lung cancer, because this lung-saving operation is safer
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ence with complex bronchial reconstruction and stress-
es the importance of lung-preserving operations.
Patients and methods 
Among 1345 patients who were operated on for primary
lung cancer from January 1985 to December 1998, 157 bron-
choplastic procedures (11.7%) for non–small cell lung cancer
were carried out. The patients undergoing atypical extended
sleeve lobectomy were selected from this series and classified
into 3 groups (A to C) according to the mode of reconstruc-
tion (Table I, Fig 1). 
Standard surgical technique was used for lobectomy and
segmentectomy until the bronchus was encountered.
Proximal and distal points of transection were determined
with at least 1 cm of the macroscopically unaffected distance
of the bronchus. Additional pieces of proximal and distal
margin were removed for frozen section evaluation. In this
type of bronchoplasty, the two bronchial stumps usually dif-
fer in size, and the distal one is quite thin and frail. A couple
of adjusting stitches in the membranous part of the larger
stump may help to make the anastomosis easier to perform.
Inside knotting of the deepest stitches is helpful even at distal
levels beyond the lobar bronchus.7 Anastomosis is performed
with interrupted sutures and full-thickness bites using 4-0
monofilament absorbable material. The sutures are placed
and tied in order from the deepest point to the lateral direc-
tion. When angioplasty is also necessary, which is often
encountered in types A and B, both the bronchial and arterial
anastomotic sites should be separated. 
The choice of operative procedure was based on curative
intent while preserving as much functional lung volume as
possible.8 Routine systematic dissection of all the hilar and
mediastinal nodes was performed in every case.10 Because of
the potential for complications of bronchial and arterial anas-
tomoses, special precautions were taken to cover them with a
pedicled substernal fat pad. Postoperatively, nasotracheal suc-
tion was carried out routinely to clear the airways. In patients
in whom auscultation or radiography was suggestive of reten-
tion of secretions, bronchoscopic therapy was performed. 
Preoperative pulmonary function studies were done to
determine first-second forced expiratory volume. In addition,
quantitative ventilation radionuclide scans and arterial blood
gas analyses were performed. Furthermore, the results of
these lung function tests at 4 to 6 months after the operation
were compared with the preoperative values. 
In patients receiving induction therapy, the regimen con-
sisted in 2 cycles of vindesine sulfate, mitomycin, and cis-
platin given intravenously at 4-week intervals. In patients
receiving preoperative irradiation, radiotherapy to the prima-
ry tumor and mediastinum was concurrently delivered until
the patient had received a cumulative dose of 40 Gy. After the
operation, none of the patients was subjected to additional
Fig 1. Sketches of the bronchial reconstruction.
Table I. Type of the procedure and reconstruction
Classification Lung resection Anastomosis Preservation
Type A Rt. upper + middle bilobectomy (+S6) Rt. main br.–lower lobe br. Rt. lower lobe (Rt. basal segment)
(Rt. main br.–basal segmental br.)
Type B Lt. upper lobectomy + S6 segmentectomy Lt. main br.–basal segmental br. Lt. basal segment
Type C Lt. lower lobectomy + lingulectomy Lt. main br.–upper division br. Lt. upper division of upper lobe
Rt., Right: Lt., left; br., bronchus; S6, superior segment of the lower lobe.
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chemotherapy or radiotherapy. Routine bronchoscopic exam-
inations were performed at 1 and 6 months after operation to
rule out local recurrence. All patients had a chest radiograph,
a computed tomographic scan of the chest, and a physical
examination during the follow-up visits, which took place at
least twice a year. Resected specimens were examined
histopathologically and histologic typing was done according
to the World Health Organization classification.11 Surgical-
pathologic staging was assigned according to the New
International Staging System for Lung Cancer.12
Results 
Extended sleeve lobectomy was performed in 15
patients (Table II). On the basis of clinical and objec-
tive functional assessment, all patients were considered
to have adequate pulmonary function to tolerate pneu-
monectomy. The group comprised 13 men and 2
women with a mean age of 64 years (range, 51-72
years). Overall follow-up ranged from 9 to 106 months.
The histopathologic diagnosis was squamous cell car-
cinoma in 13 (87%) and adenocarcinoma in 2 (13%)
patients. Four (27%) patients received induction thera-
py. Complete resection was performed in all patients.
Pulmonary angioplasty, so-called double sleeve resec-
tion, was carried out in 8 patients and performed fre-
quently in types A and B (8/10, 80%). Concerning sur-
gical-pathologic staging, 9 patients (60%) had stage
IIB disease and 6 patients had stage IIIA disease. There
Fig 2. Postoperative bronchoscopic findings showing bronchial anastomosis. A, Case A-5, the bifurcation of the
right basal segmental bronchus; B, case B-2, the trifurcation of the left basal segmental bronchus and the right
main bronchus; C, case C-1, the bifurcation of the left upper division.
Table II. Case data
Preoperative PathologicPatient No. Induction PA Local 
Type (sex, age [y]) Staging T N M Histology therapy reconstruction Result Staging T N M recurrence Prognosis
A 1 (M, 66) IIIA 3 1 0 AD + + Poor IIIA 3 2 0 No 12 mo, dead*
2 (M, 62) IIIA 3 1 0 SQ + + Good IIIA 3 1 0 No 12 mo, dead*
3 (M, 71) IIB 3 0 0 SQ — — Good IIB 3 0 0 No 106 mo, alive
4 (M, 58) IIIA 3 1 0 SQ — + Good IIIA 3 1 0 No 46 mo, alive
5 (F, 51) IIIA 3 2 0 SQ + + Good IIB 2 1 0 No 12 mo, alive
6 (F, 61) IIIA 3 1 0 AD — + Good IIIA 3 2 0 No 36 mo, alive
B 1 (M, 72) IIB 3 1 0 SQ — + Good IIB 2 1 0 No 60 mo, alive
2 (M. 65) IIIA 3 1 0 SQ — + Good IIIA 3 1 0 No 51 mo, alive
3 (M, 64) IIB 3 0 0 SQ — — Good IIB 3 0 0 No 37 mo, alive
4 (M, 70) IIB 2 1 0 SQ — + Good IIB 2 1 0 No 27 mo, alive
C 1 (M, 64) IIB 3 1 0 SQ — — Good IIB 2 1 0 No 68 mo, alive
2 (M, 68) IIB 3 1 0 SQ — — Good IIB 2 1 0 No 66 mo, alive
3 (M, 66) IIIA 2 2 0 SQ + — Good IIIA 1 2 0 No 9 mo, dead*
4 (M, 56) IIB 3 0 0 SQ — — Good IIB 3 0 0 No 15 mo, alive
5 (M, 62) IIB 3 1 0 SQ — — Good IIB 2 1 0 No 10 mo, alive
PA, Pulmonary artery; A-1 and A-5, anastomosis between right main bronchus and basal segmental bronchus; AD, adenocarcinoma; SQ, squamous cell carcinoma.
*Due to distant metastasis.
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was no operative mortality, which was defined as death
within 30 days after the operation. Bronchial recon-
struction was successful in all patients (Fig 2).
Postoperative complications during hospitalization
were infrequent and nonfatal. Acute deterioration asso-
ciated with massive pulmonary vein thrombosis
occurred in 1 patient (A-1), as a result of overstretching
of the inferior pulmonary vein and was relieved by
completion pneumonectomy. Pneumonia occurred in 2
patients, who were managed conservatively. No cases
of anastomotic stenosis developed. 
No local recurrence developed on the intrathoracic
fields, including the anastomotic sites, reimplanted
lung, or lymph nodes. All patients with stage IIB dis-
ease and half of the patients with stage IIIA disease
were alive without recurrence at the time of this report.
However, half of patients with stage IIIA disease died
within 1 year of distant metastases (Table II). 
Regarding lung function, first-second forced expira-
tory volume decreased from 1.92 ± 0.51 L before the
operation to 1.74 ± 0.43 L after the operation (n = 11),
showing that functional loss of the lung was minimal.
Arterial oxygen pressure increased from 77.0 ± 8.1 mm
Hg to 85.0 ± 11.2 mm Hg (n = 13), indicating some
amelioration of hypoxia with the operation as the turn-
ing point. Postoperative quantitative ventilation
radionuclide scans revealed that the lung ratio on the
side of the operation (operated lung/nonoperated lung)
was 26% ± 18% (n = 11). This value would have been
0% if pneumonectomy had been performed instead. 
Discussion 
Bronchoplasty is accepted as appropriate for selected
patients with resectable malignant tumors and presents
an alternative to the otherwise unavoidable pneumonec-
tomy. One should remember that the decision to per-
form bronchoplasty for a malignant tumor depends on a
subtle balance between postoperative quality of life and
the risk of recurrence plus postoperative complications.
One possible problem of bronchoplasty for malignant
disease is the potentially increased rate of local recur-
rence. The review by Tedder and associates5 showed
that the local recurrence rate after sleeve lobectomy was
12.5% (84/673), although most authors did not specify
whether local recurrence developed at the suture line or
within the thorax. In this series, local recurrence could
not be found either in the intrathoracic lymph nodes or
in pulmonary sites. Until recently, this procedure usual-
ly was mainly indicated for patients with a compro-
mised lung reserve.4,5,13 We, however, performed it fre-
quently and actively not only in patients with
compromised lung function but also in those with non-
compromised lung function.14 Although bronchoplastic
procedures were reported to be appropriate for approx-
imately 5% to 8% of patients with a resectable malig-
nant pulmonary tumor,5,15 we could apply this proce-
dure in 11.7% (157/1345) of our patients. In any case, it
is essential to keep a macroscopically sufficient margin
of safety, as well as to perform a rapid frozen section
analysis during the operation.
Because we always keep lung-saving procedures in
mind, pneumonectomy has been performed infrequently
and much less than sleeve lobectomy. Also, compared
with pneumonectomy, sleeve lobectomy is not associat-
ed with an increase in local recurrence. In consequence,
we have fewer early postoperative complications such as
pneumonia, pulmonary infarction, or pulmonary edema,
and curative resection can be done with a low operative
mortality.8,10,16 Pneumonectomy, which limits pul-
monary reserve and results in an increased pulmonary
artery pressures, results in greater long-term cardiopul-
monary disability and worse quality of life than standard
lobectomy or sleeve lobectomy.17 Pneumonectomy has
been considered to be a predisposing, but not exclusive-
ly causative, factor for cardiopulmonary death.18 We
consider that pneumonectomy is a disease in itself and
should be avoided at all costs. Although most surgeons
might have selected pneumonectomy for the patients in
this series, we tried to resect as little lung tissue as pos-
sible and performed lung-preserving operations involv-
ing anastomosis between the main bronchus and the seg-
mental bronchus. 
The complication rate in the present series was low,
local recurrence did not occur, and the survival was
acceptable. In 1 patient, pulmonary vein thrombosis
occurred at the level where the reconstructed basal seg-
ment, accompanied by sleeve angioplasty of the pul-
monary artery, had been pulled up with tension on the
carina. Learning from this case, we avoided this type of
complication by performing a pericardial incision
around the inferior pulmonary vein. 
Invasion of the bronchus by central tumor, in associa-
tion with normal nodes, was the most suitable indica-
tion. More recently, several reports have shown accept-
able long-term results for sleeve resection of lung
cancer with N1 disease but not with N2 disease.19,20
None of the patients in our series had local recurrence,
indicating a satisfactory local control of central lung
cancer by this extended sleeve lobectomy, which saved
the portion of the lobes not involved with the tumor. The
indication for sleeve resection in patients with N2 dis-
ease (stage IIIA) is controversial and requires circum-
spection. However, we do not think that pneumonecto-
my instead of sleeve lobectomy would have resulted in
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better survival for patients with N1 or N2 disease,
because most patients died of distant metastases. 
The results of this study clearly reveal that extended
sleeve lobectomy is a satisfactory surgical treatment for
lung cancer in terms of operative risk, curability, and
lung function after the operation. The indications for
this procedure for lung cancer, which is technically
more demanding than pneumonectomy, have to be clar-
ified, and the decision to select this procedure may be
influenced by the surgeon’s skills. However, we suggest
that this extended sleeve lobectomy should be per-
formed for centrally located lung cancer whenever fea-
sible, since this procedure eradicated cancer to a degree
similar to that of pneumonectomy and offered the pos-
sible advantages of lower operative mortality rates,
equal if not better survival, and improved quality of life. 
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